Trial · NCT01589302
Adverse events158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
121 to 140 of 158
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Urinary Tract Infection | Infections and infestations | Treatment (Ibrutinib) | 3 | 152 | 8 |
| serious | Fall | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Fracture | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Injury, Poisoning and Procedural Complications - Other | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 3 | 152 | 3 |
| serious | Intestinal Stoma Obstruction | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Postoperative Hemorrhage | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Spinal Fracture | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Dehydration | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 3 | 152 | 3 |
| serious | Hypercalcemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 2 | 152 | 2 |
| serious | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Hyperkalemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Hyponatremia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Metabolism and Nutrition Disorders - Other | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 4 | 152 | 4 |
| serious | Arthralgia | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 2 | 152 | 3 |
| serious | Back Pain | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 3 | 152 | 3 |
| serious | Generalized Muscle Weakness | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Muscle Weakness Left Sided | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 1 | 152 | 1 |
| serious | Musculoskeletal and Connective Tissue Disorder - Other | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 3 | 152 | 3 |
| serious | Intracranial Hemorrhage | Nervous system disorders | Treatment (Ibrutinib) | 2 | 152 | 2 |
| serious | Leukoencephalopathy | Nervous system disorders | Treatment (Ibrutinib) | 2 | 152 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589302/events?page=7